Baker Avenue Asset Management LP Has $15.27 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Baker Avenue Asset Management LP raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.2% during the fourth quarter, Holdings Channel reports. The firm owned 26,358 shares of the medical research company’s stock after buying an additional 2,229 shares during the period. Baker Avenue Asset Management LP’s holdings in Thermo Fisher Scientific were worth $15,273,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Assetmark Inc. raised its position in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $41,393,000. Mackenzie Financial Corp raised its position in shares of Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after acquiring an additional 62,790 shares during the last quarter. NEOS Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 28.6% during the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after acquiring an additional 11,415 shares during the last quarter. Finally, Factory Mutual Insurance Co. raised its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock valued at $47,985,000 after acquiring an additional 2,500 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 1.9%

Shares of NYSE:TMO opened at $456.64 on Thursday. The company’s 50-day moving average price is $479.12 and its two-hundred day moving average price is $535.54. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The stock has a market capitalization of $169.70 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 1.98 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the previous year, the firm posted $5.15 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TMO. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Finally, Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $616.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.